studies have shown that idiopathic RBD (iRBD) patients may eventually be diagnosed with an -synucleinopathy such as Parkinson's disease (PD), multiple system atrophy, or dementia with Lewy bodies. [1] [2] [3] Additionally, approximately 35-50% of patients with PD have RBD (PD + RBD); these patients tend to have the akinetic-rigid dominant subtype of PD and exhibit severe nonmotor symptoms. [4] PD with mild cognitive impairment (PD-MCI), as a transitional stage, identifies those individuals at increased risk for PD dementia. [5] [6] [7] Despite the lack of consensus criteria, 19-38% of nondemented PD patients have MCI. [8] Furthermore, in those individuals with PD for at least 10 years, the cumulative prevalence of PD dementia is approximately 75-90%. [9] Of note, most studies have demonstrated that the prevalence of MCI is significantly higher in PD + RBD patients than in PD without RBD (PD-RBD) individuals. [10] However, seldom study has investigated the relation between the severity of RBD and the different domains of cognitive impairment.
In this study, we performed extensive neuropsychological assessments based on the recommendations from 2011 Movement Disorder Society (MDS) Task Force [11] to compare the cognitive level and prevalence of MCI in PD + RBD patients, PD-RBD patients, iRBD patients, and healthy control (HC) subjects. Furthermore, we assessed the ability of clinical factors to predict MCI in PD patients and explored the specific domains affected by RBD.
Methods
This study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University, and all patients provided informed written consent before participating. Overview of the methods has been described in Supplementary Material 1.
Subjects
A total of 125 subjects, including 74 PD patients (32 PD + RBD and 42 PD-RBD), 15 iRBD patients, and 36 age-, sex-, and education level-matched HC subjects were recruited from the Center of Parkinsonism and Movement Disorders from February 2014 to May 2015 in the Second Affiliated Hospital of Soochow University. The HC participants were partners or friends of PD patients.
All subjects were between 40 and 80 years old and had at least 5 years of schooling. The diagnosis of PD was established according to the clinical diagnosis criteria of the United Kingdom PD Society. To reduce the influence of confounding factors such as bradykinesia and tremor on cognitive scores, we only included those patients whose Hoehn-Yahr (H-Y) stage ≤ 2.5 and Unified Parkinson's Disease Rating Scale (UPDRS) part III score ≤ 35. Clinical RBD in patients with PD was diagnosed according to affirmative responses to the Mayo Sleep Questionnaire (MSQ), [12, 13] as well as the RBD Screening Questionnaire (RBDSQ) (a sensitivity of 0.842, and specificity of 0.962 for detecting RBD). [14] A cut-off score of 7 on the RBDSQ was used to differentiate PD + RBD (≥ 7) patients from PD-RBD patients (< 7). All iRBD patients and 35 PD patients underwent video-polysomnography to confirm or refute the diagnosis of RBD. The diagnosis of RBD for these patients was determined using the clinical criteria established by the American Academy of Sleep Medicine (AASM), the International Classification of Sleep Disorders third edition.
A total of 16 subjects were excluded because of the presence of severe dementia (Mini-Mental State Examination [MMSE] score < 24 and diagnosis of dementia according to the MDS clinical diagnostic criteria). [15] Patients were also excluded if they had a major psychiatric disease (major depression or anxiety) diagnosed according to the Diagnostic Statistical Manual-IV criteria, or if they were unwilling to cooperate with the cognitive tests.
Neuropsychological assessment
All subjects underwent a neuropsychological examination. The PD patients completed the tests within 1-2 h after taking their usual medications. Tests of global cognition included the MMSE and montreal cognitive assessment (Beijing version). The comprehensive tests were grouped into 5 cognitive domains based on the MDS task force recommendations [11] and prior studies: (1) We classified patients as having MCI if they scored ≥ 1.5 standard deviations (SDs) below the age-and education-corrected norms on at least two tests, either within a single cognitive domain or across different cognitive domains. [11] 
Clinical assessment
The information of basic demographics, diseases and medication history, and comorbid diseases was obtained for all subjects. Motor manifestations of PD patients were evaluated in the "on" state. These manifestations included the UPDRS-total and subscales I-IV, the H-Y stage, and the levodopa-equivalent daily (LED) dose. Additionally, we defined the akinetic-rigid/ tremor (AR/T) ratio according to the Schiess classification [16] and the axial-limb ratio as the sum of UPDRS III items 18, 19, 22, and 27-30 divided by UPDRS III items 20-26. The frequency of falls and freezing [17] was measured according to scores for questions 6 and 7 on part II of the UPDRS.
Nonmotor symptoms and quality of life were also assessed. The nonmotor symptoms questionnaire [18] was used as the screening instrument for hypersalivation, olfactory dysfunction, constipation, and urinary urgency, with answers recorded as "present" or "absent". Daytime somnolence and quality of life were evaluated using the Epworth Sleepiness Scale (ESS) and the PD questionnaire (PDQ-39), respectively.
Manifestations of rapid eye movement sleep behavior disorder
The severity of RBD symptoms was assessed using the RBDQ-HK and the RBDSQ. For those patients who completed an overnight video-polysomnography study (Compumedics-E series, Australia) (35 PD and all iRBD patients), we calculated the tonic chin electromyography activity (tonic density) and the phasic chin electromyography density activity (phasic density) according to a previously published method [19] and the criteria of the AASM. 
Statistical analysis

results
Demographics and clinical characteristics
Tw e n t y -f o u r s u b j e c t s r e f u s e d t o u n d e rg o t h e neuropsychological assessment, and 14 and 13 PD patients were diagnosed with PD dementia and depression, respectively. Thus, 125 subjects were ultimately included in our study. Of these subjects, 73 were men and 52 were women, with a mean age of 62.7 ± 8.1 years (range: 47-75 years) and mean education duration of 9.8 ± 2.7 years (range: 5-18 years). According to MSQ criteria and RBDSQ scores, the participants were divided into four groups: PD + RBD, PD-RBD, iRBD, and HC. Our RBD patients confirmed by PSG showed behavior/vocalization in REM sleep, or REM sleeps without atonia. The PD + RBD patients exhibited higher percentages of tonic (17.70 ± 9.20% vs. 3.73 ± 3.56%, t = −5.66, P < 0.05) and phasic EMG activities (18.54 ± 11.08% vs. 5.82 ± 5.29%, t = −4.891, P < 0.05) than PD-RBD patients. 
Neurological test scores
The neurological test scores and results of analyses are presented in Table 2 . MCI was diagnosed in 14 of the 42 PD-RBD patients (33%), 20 of the 32 PD + RBD patients (63%), 5 of 15 iRBD patients (33%), and 3 of the 36 HC subjects (8%). MCI was significantly more frequent in PD + RBD patients than in PD-RBD patients ( 2 = 6.221, P = 0.013). Table 3 displays the results of the regression analyses of factors associated with MCI. First, the colinearity among clinical factors was determined, and it was subsequently reduced by removing some factors. The remaining factors, which are shown in Table 3 , were entered into the univariate regression analysis. Factors found to be significantly associated with MCI during univariate logistic regression analyses were included in the subsequent multivariate analyses. After adjusting for covariates, significant risk factors for MCI were education ( = −0. 
Univariate and multivariate binary logistic regression analyses of clinical factors associated with minimal cognitive impairment
Correlation analysis
We further examined associations between the severity of RBD symptoms and cognitive levels via correlation analysis. Table 4 shows that higher RBDSQ scores were significantly associated with poorer performance on the TMT-B (errors) (r = 0.267, P = 0.026) and AVLT (delayed recall) (r = −0.313, P = 0.008). Higher RBD-HK scores were associated with worse scores on the TMT-B (r = 0.249, P = 0.038), AVLT (delayed recall) (r = −0.246, P = 0.040), and Rey-O figure (copy) test (r = −0.290, P = 0.015). These effects were observed after controlling for age, education duration, and UPDRS part III score.
dIscussIon
In this study, we used the standard diagnostic criteria for PD-MCI proposed by the MDS. Our results indicated that cognitive function, including delayed memory, was worse in PD + RBD patients than in PD-RBD patients. The number of PD + RBD patients who screened positive for MCI was high, and our results indicated that RBD was a significant independent risk factor for MCI. We also observed clear associations between RBD symptoms and different domains of PD-MCI.
Many investigators have studied the clinical characteristics of patients with PD + RBD. Some studies found that RBD in PD was associated with a higher LED. [20] A recent study reported that PD + RBD was a special type of disease characterized by less of a tremor, higher frequency of falls, and a lower amplitude of response to medications dose. [4] Nonetheless, other studies reported different results. Rolinski et al. [21] found that PD + RBD patients did not differ from PD-RBD patients with respective to motor phenotype and scored comparably on objective motor scales; however, PD + RBD patients exhibited greater sleepiness, depression, and cognitive impairment. Given the influence that confounding factors such as bradykinesia and tremor can have on cognitive tests, we adjusted for age, education duration, PD duration, and UPDRS part III score in the current study. After these adjustments, we found that PD + RBD patients were more likely to have only olfactory dysfunction and daytime somnolence. The discrepancy between our results and those of previous studies was likely attributable to our adjustments because we found more akinetic rigid subtypes in the PD + RBD group before adjustment. Thus, when PD-RBD and PD + RBD patients have equivalent motor symptoms, those with PD + RBD have a greater prevalence of olfactory dysfunction and daytime somnolence.
Previous studies examining associations between RBD and cognition in patients with PD used different tests and cut-offs to measure MCI, and not surprisingly, these studies have produced discrepant results. In most studies, PD patients performed worse in tasks of attention/executive functions. [22] In our results, we additionally found the lower performance on one of two tests of visuospatial function in PD-RBD patients compared to HC. Importantly, we found a verbal and visuospatial memory (Rey-O figure, recall) deficiency in PD + RBD patients, but not in PD-RBD patients, which was opposite to the findings reported by Gagnon et al. [10] Our results were consistent with those of previous studies, which indicated that verbal memory impairment plus executive dysfunction are associated with the development of dementia in patients with PD. [23] As the cognitive tests are inextricably linked, we did not observe dysfunction in one single domain in PD + RBD, but these patients are more likely to have delayed memory impairment.
The pathophysiological mechanism responsible for our findings of impaired cognitive function in PR + RBD patients is unclear. The pedunculopontine nucleus (PPN) plays an important role, providing the majority of cholinergic input to the thalamus, as well as cholinergic input to various other structures, including the nucleus basalis of Meynert (nbM), striatum, substantia nigra, subthalamic nucleus, globus pallidus interna, cerebellum, and the spinal cord. [24] Cholinergic output is sent to the cerebral cortex and thalamic nuclei by the nbM. Degeneration of the PPN and nbM occurs in PD, with the degree of degeneration correlating with motor and cognitive impairment, respectively. [24] Furthermore, the PPN is involved in the influence of sleep-wake cycles by the basal ganglion, [25] and acetylcholine is released in areas of the brain related to consciousness and conscious awareness. [24] The prevalence of MCI in our four groups ranged from highest in the PD + RBD group, followed in descending order by the PD-RBD, iRBD, and HC groups. Unlike some cohort studies, the prevalence was not high in those with iRBD. [10] In a recent study, MCI and depression did not clearly predict clinical neurodegeneration in iRBD, [26] but indicated transition to dementia. In our multivariate binary logistic regression analyses, except for education duration, scores on the UPDRS part III and RBD were the only risk factors for PD-MCI. The association between AR/T + mixed subtype and MCI did not quite achieve statistical significance (P = 0.059), and it is possible that this would have been significant with a larger number of subjects. In our study, patients with major depression and anxiety were excluded, which may have explained why we detected no association between MCI and depression during the multivariate logistic regression analysis. Our findings thus suggested that cognitive function could be aggravated by RBD and the severity of the motor manifestations.
In our study, correlation analysis showed that the severity of RBD symptoms was associated with impaired executive function and delayed memory. Poorer visuospatial function correlated with RBD-HK but not RBDSQ. The current leading two explanations for decreased cognitive performance in patients with PD and concomitant RBD are as follows: One explanation states that REM sleep is associated with memory consolidation and long-term stabilization, [27] therefore, disruptions of REM sleep could directly perturb memory function; [24] the other explanation states that interrupted REM sleep can lead to cholinergic deficits in PD patients. Our findings were consistent with the hypothesis that the severity and frequency of RBD could exacerbate cognitive impairments of executive function, verbal delayed memory, and visuospatial function.
Several limitations of this study should be taken into consideration. For example, the study had a relatively small sample size and a cross-sectional design. Second, many of the subjects did not undergo polysomnography. Third, the neuropsychological tests used to represent function within cognitive domains varied to some extent from those used in previous studies. For example, the SVFT was divided into language function in our study. [22] In conclusion, we confirmed that RBD may be a marker of a specific subtype of PD, which is more likely to be characterized by olfactory dysfunction and daytime somnolence, when patients have equivalent motor symptoms. Moreover, RBD is a crucial risk factor for MCI, including delayed memory function. Furthermore, the clinical severity of RBD correlates with poorer performance in executive function, delayed memory, and visuospatial function. 
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.
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